Dynavax Elects Directors and Approves Key Amendments

Dynavax ( (DVAX) ) has shared an update.

On April 14, 2025, Dynavax held its Annual Meeting where stockholders elected four Class I directors to serve until the 2028 meeting. The meeting also saw the approval of executive compensation, the ratification of Ernst & Young LLP as the independent auditor, and the amendment of the Certificate of Incorporation to declassify the Board. However, a stockholder proposal to amend the bylaws without stockholder approval was not passed.

The most recent analyst rating on (DVAX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.

Spark’s Take on DVAX Stock

According to Spark, TipRanks’ AI Analyst, DVAX is a Neutral.

Dynavax’s overall score is affected by weak financial performance due to declining revenues and net losses, which are somewhat offset by a strong balance sheet and adequate cash flow management. Technical indicators are bearish, and the stock’s valuation is unappealing due to the negative P/E ratio. The earnings call provides a positive outlook with revenue growth and strategic advancements, which somewhat mitigates the financial and technical weaknesses. Continued focus on growth and cost management will be key to improving the company’s financial health.

To see Spark’s full report on DVAX stock, click here.

More about Dynavax

Average Trading Volume: 2,276,872

Technical Sentiment Signal: Sell

Current Market Cap: $1.22B

Find detailed analytics on DVAX stock on TipRanks’ Stock Analysis page.